GLYLINA 5

GLYLINA-5 by Voithea Healthcare is a targeted anti-diabetic formulation containing Linagliptin 5mg, a DPP-4 inhibitor that enhances the body’s natural ability to regulate blood sugar levels. It works by increasing incretin levels, which in turn stimulate insulin release and decrease glucagon production in a glucose-dependent manner.

Ideal for managing type 2 diabetes, GLYLINA-5 offers once-daily convenience, a low risk of hypoglycemia, and no required dose adjustments in renal impairment. This reflects Voithea Healthcare’s commitment to delivering innovative and effective solutions for long-term glycemic control.